Skip to main content
Neural Therapeutics Inc. logo

Neural Therapeutics Inc. — Investor Relations & Filings

Ticker · NURL ISIN · CA64134N2032 LEI · 894500KBZO3KS9715774 CSE Manufacturing
Open in API
Filings indexed 141 across all filing types
Latest filing 2025-11-28 Regulatory Filings
Country CA Canada
Listing CSE NURL

About Neural Therapeutics Inc.

https://neuraltherapeutics.ca/

Neural Therapeutics Inc. is an ethnobotanical drug discovery and development company operating in the pharmaceutical and nutraceutical sectors. It focuses on developing therapeutic drugs for mental illnesses, including those related to substance abuse, and over-the-counter dietary supplements. The company integrates modern scientific research with traditional indigenous knowledge regarding psychoactive plants and whole plant extracts. Initial R&D centers on the San Pedro cactus (Echinopsis pachanoi), which contains mescaline. Neural Therapeutics pursues a dual-path strategy to develop both pharmaceutical and nutraceutical products, aiming for whole plant utilization and zero waste.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a 'Certification of Annual Filings' (Form 52-109FV1) signed by the CEO. This is a regulatory requirement for venture issuers to certify the accuracy of their annual financial statements and MD&A. Since it is a standalone regulatory certification document rather than the annual report itself, and it does not fit into the other specific categories like '10-K' or 'AR', it is best classified as a Regulatory Filing (RNS).
2025-11-28 English
Annual MD&A - English.pdf
Management Reports Classification · 100% confidence The document is explicitly titled 'MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS' for the years ended July 31, 2025 and 2024. It provides a detailed narrative explanation of the company's financial results, business highlights, corporate structure, and management's assessment of operations, which is the standard content for an MD&A report. It is not an earnings release (which is a summary) nor an annual report (which would include the full audited financial statements), but rather the management's commentary section typically filed alongside or as part of the annual reporting package.
2025-11-28 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 95% confidence The document contains a full set of audited financial statements for Neural Therapeutics Inc., including an Independent Auditor's Report, Statements of Financial Position, Statements of Loss and Comprehensive Loss, Statements of Cash Flows, and Statements of Changes in Shareholders' Equity for the years ended July 31, 2025 and 2024. Since this is a standalone audit report and financial statement package rather than a full 10-K annual report (which would include extensive business descriptions, risk factors, and management discussion), it is classified as an Audit Report/Information document. FY 2025
2025-11-28 English
News release - English.pdf
Regulatory Filings
2025-11-06 English
Business acquisition report - English.pdf
Regulatory Filings
2025-10-26 English
Consent letter(s).pdf
Audit Report / Information Classification · 75% confidence The document is an auditor’s consent letter addressed to securities regulators, granting permission to include the independent auditor’s report within a Form 51-102F4 Business Acquisition Report. It is not an Annual Report or earnings release but directly relates to audit information. Therefore it falls under Audit Report / Information. FY 2024
2025-10-26 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.